Clinical Trial

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.
Protocol Amendment History 1 change
minor Completion pushed: 2026-07 -> 2027-07 2026-08-12
Trial Details
NCT Number NCT03215095
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: AstraZeneca, MedImmune LLC
Conditions Thyroid Cancer
Enrollment 11 participants
Start Date 2017-07-10
Primary Completion 2023-02-06 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-11